How Has the Addisons Disease Market Evolved Historically and What is its Current Size?
The addisons disease market has seen considerable growth due to a variety of factors.
• The size of the market for Addison's disease has experienced fast-paced growth over the past couple of years. It is projected to rise from $2.05 billion in 2024 to $2.25 billion in 2025, with a compound annual growth rate (CAGR) of 10.0%.
The significant growth during the historic period is due to multiple factors including an upsurge in Addison's disease cases globally, increased understanding about adrenal insufficiency, expansion in healthcare spending, increased occurrence of autoimmune diseases, and a growing aging population.
What Is The Projected Growth Of The Addisons Disease Market?
The addisons disease market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipated robust growth will be witnessed in the Addison's disease market over the next few years, elevating to a value of $3.26 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 9.7%.
Several factors contribute to this projected growth during the forecast period including, increased urgency for sophisticated therapy options, a growing emphasis on early detection methods, an upward trend in congenital adrenal hyperplasia instances, the proliferation of telemedicine facilities, and a spike in adrenal tuberculosis cases. The forecast period will also reflect some key trends such as enhancements in lab test procedures, advancements in hormone replacement treatments, progress in imaging technologies, the introduction of long-acting injectable formulations, and the incorporation of artificial intelligence in diagnostic instruments.
What Are The Key Drivers Fueling Growth In The Addisons Disease Market?
The increase in autoimmune disease instances is predicted to fuel the expansion of the market for Addison's disease. Autoimmune diseases happen when the body's immune system erroneously targets its own healthy tissues, causing inflammation and harm. Genetic predisposition, pollutants and dietary changes as environmental factors, and lifestyle influences like stress and lack of physical activity contribute to the rise in autoimmune disease prevalence. As many patients with autoimmune diseases also develop other related conditions, the likelihood of Addison's disease also increases. For example, Versorgungsatlas.de, a German organization, reported that in 2022, out of 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, marking a raw prevalence rate of 8.61% - an increase from earlier estimates ranging from 3% to 9%. Consequently, the rising instances of autoimmune diseases are propelling the Addison's disease market's growth.
What Are The Principal Market Segments In The Global Addisons Disease Industry?
The addison's disease market covered in this report is segmented –
1) By Type: Primary Adrenal Insufficiency, Secondary Adrenal Insufficiency, Tertiary Adrenal Insufficiency
2) By Drug Class: Oral Corticosteroid, Hydrocortisone, Fludrocortisone, Corticosteroid Injections
3) By Diagnosis: Laboratory Testing, Imaging Testing
4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users
Subsegments:
1) By Primary Adrenal Insufficiency: Autoimmune Addison's Disease, Infectious Addison's Disease, Other causes of primary adrenal insufficiency
2) By Secondary Adrenal Insufficiency: Pituitary gland dysfunction, Hypothalamic dysfunction
3) By Tertiary Adrenal Insufficiency: Hypothalamic or pituitary suppression due to long-term steroid use, Other causes of tertiary adrenal insufficiency
Pre-Book The Addisons Disease Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Addisons Disease Industry?
Key businesses in the Addison's disease market, such as regenerative treatments, are being prioritized for development by major firms to improve patient outcomes and treatment options. They aim to lessen the reliance on lifelong hormone replacement therapies by evoking natural adrenal function in the body. Regenerative treatments are medical strategies adopted to replace or regenerate human organs, cells, or tissues to restore their normal functionality and heal cases of disease, injury or degeneration. For example, in July 2024, Eton Pharmaceuticals, Inc., a public pharmaceutical company based in the US focusing on creating and marketing innovative treatments for rare diseases, has received FDA approval for its New Drug Application (NDA) for ET-400. This is a distinct formulation of hydrocortisone oral solution, which is more convenient to transport and store than other versions which may require refrigeration. The liquid format of ET-400 caters to the needs of young patients who might struggle with swallowing traditional tablets and also enables accurate dosage.
Who Are the Key Players In The Addisons Disease Market?
Major companies operating in the addison's disease market are:
• Pfizer Inc.
• Roche Holding AG
• Merck & Co. Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• Novartis AG
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline plc
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH
• Sandoz
• Ipsen S.A.
• Neurocrine Biosciences Inc.
• Recipharm AB
• Accord Healthcare
• Eton Pharmaceuticals
• DuoCort Pharma
• Diurnal Group plc
• Roxane Laboratories Inc.
What Are The Regional Insights Into The Addisons Disease Market?
North America was the largest region in the addison's disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the addison's disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
